<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03634514</url>
  </required_header>
  <id_info>
    <org_study_id>PPES 002/18</org_study_id>
    <nct_id>NCT03634514</nct_id>
  </id_info>
  <brief_title>Non-inferiority Evaluation of Pain Intensity After Biomatrop (Somatropin) Application in Relation to Hormotrop (Somatropin), in Healthy Subjects</brief_title>
  <official_title>National, Monocentric, Randomized, Double-blind, Controlled, Crossover Clinical Trial, to Evaluate the Non-inferiority of Pain Intensity After the Application of Recombinant Human Somatropin - Biomatrop (Biosintética Farmacêutica) in Relation to Recombinant Human Somatotropin - Hormotrop (Bergamo), Single Dose, in Healthy Subjects of Both Genders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ache Laboratorios Farmaceuticos S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ache Laboratorios Farmaceuticos S.A.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, Double-blind, Controlled, Crossover, in which 68 subjects (34 males and 34&#xD;
      females) will receive, in each stage, an application of 4 UI, subcutaneous, single dose, of&#xD;
      the investigational drug (Recombinant Human Somatropin - Biomatrop) and the comparator&#xD;
      (Recombinant Human Somatropin - Hormotrop) according to randomization to evaluate the&#xD;
      Non-inferiority of Pain Intensity After the Application of Hormotrop, using Visual Analogue&#xD;
      Scale (0-10cm) and record the incidence of adverse events.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">August 27, 2018</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Intensity</measure>
    <time_frame>1 hour</time_frame>
    <description>Report the Pain Intensity using Visual Analogue Scale (0-10cm)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Application of Biomatrop</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of Recombinant Human Somatropin - Biomatrop is administered. The pain intensity is evaluated using visual analogue scale (0-10cm) and record the incidence of adverse events.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Application of Hormotrop</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single dose of Recombinant Human Somatropin - Hormotrop is administered. The pain intensity is evaluated using visual analogue scale (0-10cm) and record the incidence of adverse events.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant human growth hormone - Biomatrop</intervention_name>
    <description>The subjects who recieve Biomatrop first, after a period maximum of 24 hours will recieve a dose of Hormotrop.</description>
    <arm_group_label>Application of Biomatrop</arm_group_label>
    <arm_group_label>Application of Hormotrop</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant human growth hormone - Hormotrop</intervention_name>
    <description>The subjects who recieve Hormotrop first, after a period maximum of 24 hours will recieve a dose of Biomatrop.</description>
    <arm_group_label>Application of Biomatrop</arm_group_label>
    <arm_group_label>Application of Hormotrop</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Skin phototype from 2 to 4, according to Fitspatrick classification:&#xD;
             http://www.sbd.org.br/dermatologia/pele/cuidados/classifica cao-dos-fototipos-de-pele/&#xD;
             ;&#xD;
&#xD;
          -  Subjects with normal laboratory, type 1 urine exam, vital signs and ECG results;&#xD;
&#xD;
          -  Weight ≥ 50kg and Body Mass Index ≤ 30 ;&#xD;
&#xD;
          -  Healthy subject according with clinical history&#xD;
&#xD;
          -  Ability to understand and consent their participation in this clinical study,&#xD;
             expressed by signing the Informed Consent Form (ICF);&#xD;
&#xD;
          -  Subject who have negative results for stool protoparasitological examination&#xD;
             accomplished in clinical study. Subjects with positive results for Endolimax nana,&#xD;
             Entamoeba hartmanni, Entamoeba coli, Iodamoeva btshlii, Chilomastix mesili,&#xD;
             Trichomonas hominis, Retortamonas intestinalis e Enteromonas hominis will be able to&#xD;
             be included in the study. At the end of the study those subjects will be guided to&#xD;
             treatment according to clinic investigator criteria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Laboratory and clinical exam results out of normal range values, unless considered by&#xD;
             physician clinically irrelevant;&#xD;
&#xD;
          -  Positive sorology for HIV;&#xD;
&#xD;
          -  Positive sorology for Hepatitis B;&#xD;
&#xD;
          -  Positive sorology for Hepatitis C;&#xD;
&#xD;
          -  Known hypersensitivity to the components of the medicines used during the study or&#xD;
             related chemical compounds;&#xD;
&#xD;
          -  Subjects that has participated in clinical trial protocols in the last twelve (12)&#xD;
             months (National Board of Health- Resolution 251 of 07 August 1997, Part III, sub-item&#xD;
             J), unless the investigator considers that there may be a direct benefit to it;&#xD;
&#xD;
          -  Use of any type of regular medication within two (2) weeks or five (5) half-lives&#xD;
             (whichever lasts longer) before administration of the first dose of the&#xD;
             investigational product (IP). The eventual use of medication, which in the opinion of&#xD;
             the Principal Investigator or physician does not interfere with the pharmacokinetics&#xD;
             of IP in study will not be considered as exclusion criteria;&#xD;
&#xD;
          -  History of alcohol abuse or having ingested alcoholic drink 24 hours prior to IP&#xD;
             administration;&#xD;
&#xD;
          -  History of psychotropic drug use and / or positive outcome for any of the components&#xD;
             of the drug abuse test for amphetamine, benzoylecgonine (cocaine), benzodiazepines,&#xD;
             methamphetamine, opiates, morphine, etrahydrocannabinol-THC (Marijuana / Marijuana).&#xD;
             Subjects who used marijuana and hashish in less than three months before the&#xD;
             consultation will be excluded. For drugs like cocaine, crack and heroin will be&#xD;
             excluded subjects who present any use history;&#xD;
&#xD;
          -  Any finding of clinical observation, laboratory abnormality or therapy which, in the&#xD;
             opinion of the investigator, may put the subject at risk or interfere with the purpose&#xD;
             of the study;&#xD;
&#xD;
          -  The subject have any condition that in investigator's opinion prevents him/her from&#xD;
             participating in the study;&#xD;
&#xD;
          -  History of food allergy or hyperactivity to medications or food;&#xD;
&#xD;
          -  Regular smokers or ex-smokers who have stopped for less than 6 months;&#xD;
&#xD;
          -  Subjects who have a relationship of kinship to second degree or any bond with the&#xD;
             sponsor or research center employees;&#xD;
&#xD;
          -  Subjects with the following ECG changes: sinus tachycardia with heart rate ˃ 120 bpm;&#xD;
             bradycardia sinus heart rate &lt;50 bpm; atrial tachycardia, ventricular or junctional;&#xD;
             ectopic atrial rhythm; atrial fibrillation; atrial flutter; accelerated&#xD;
             idioventricular rhythm; locking atrium ventricular (BAV) of 1º, 2º and 3º degrees;&#xD;
             ventricular pre-excitation; complete blockage of right or left branch; rhythm of&#xD;
             pacemaker; supraventricular tachycardia (nodal tachycardia, ventricular atrial&#xD;
             tachycardia) or any other clinically significant;&#xD;
&#xD;
          -  Male subjects who do not agree to use acceptable contraceptive methods: (a)&#xD;
             contraceptive methods for the participant: barrier preservative, except for&#xD;
             (vasectomy) or for participants who declare that they do not engage in sexual&#xD;
             practices or exercise them non-reprodutively; (b) contraceptive methods for the&#xD;
             partner: oral contraceptive, intravenous contraceptive, intrauterine device (IUD),&#xD;
             hormonal implant, hormonal transdermal patch, tubal ligation, and barrier methods&#xD;
             except for female partners that are surgically sterile (bilateral oophorectomy or&#xD;
             hysterectomy), or menopause for at least 01 (one) year;&#xD;
&#xD;
          -  Women who do not agree to use acceptable contraceptive methods (oral contraceptive,&#xD;
             intravenous contraceptive, intrauterine device (IUD), hormonal implant, barrier&#xD;
             methods, hormonal transdermal patch and tubal ligation); except for those surgically&#xD;
             sterile (bilateral oophorectomy or hysterectomy), menopause for at least one year, and&#xD;
             participants who report not engaging in sexual practices or non-reproductive&#xD;
             practices;&#xD;
&#xD;
          -  Women in pregnancy or nursing period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sérgio Alberto Cunha Vêncio</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto de Ciências Farmacêuticas (ICF)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elisangela Rorato</last_name>
    <phone>+55 11 2608-6130</phone>
    <email>Elisangela.rorato@ache.com.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Instituto de Ciências Farmacêuticas</name>
      <address>
        <city>Goiânia</city>
        <state>Goiás</state>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Sérgio Vencio</last_name>
      <phone>+55 62 3240-1900</phone>
      <email>sergio.vencio@icf.com.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 13, 2018</study_first_submitted>
  <study_first_submitted_qc>August 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2018</study_first_posted>
  <last_update_submitted>August 16, 2018</last_update_submitted>
  <last_update_submitted_qc>August 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

